Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Preliminary experience with pure antiestrogens.

A Howell1

  • 1CRC Department of Medical Oncology, University of Manchester, Christie Hospital, United Kingdom. maria.parker@christie-tr.nwest.nhs.uk

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|March 28, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A new, ultra-stable lab for nano-metrology of x-ray optics at Diamond Light Source.

The Review of scientific instruments·2025
Same author

Socioeconomic and ethnic disparities in preterm births in an English maternity setting: a population-based study of 1.3 million births.

BMC medicine·2024
Same author

Tamoxifen evolution.

British journal of cancer·2023
Same author

Safety of the use of gold nanoparticles conjugated with proinsulin peptide and administered by hollow microneedles as an immunotherapy in type 1 diabetes.

Immunotherapy advances·2022
Same author

The impact of the COVID-19 pandemic on UK medical education. A nationwide student survey.

Medical teacher·2021
Same author

Patient reported outcome measures in a cohort of patients at high risk of breast cancer treated by bilateral risk reducing mastectomy and breast reconstruction.

Journal of plastic, reconstructive & aesthetic surgery : JPRAS·2021
Same journal

Clinical Validation of a Multiplex Urine Biomarker Assay for Surveillance of Recurrent Bladder Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Epigenetic Liquid Biopsy Enables Universal Mutation-Agnostic Molecular Surveillance for High-Risk Neuroblastoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Claudin 18.2 Targeting: A Pan-Cancer Perspective.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

High-Sensitivity ctDNA Analysis Uncovers Relevant Signals Missed by NGS in Pancreatic Cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

Pediatric Brain Tumor Consortium phase 1 study of CD40 agonist sotigalimab in pediatric and young adult patients with recurrent CNS tumors and newly-diagnosed DIPG.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same journal

A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without cobimetinib in previously-treated unresectable biliary tract cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
See all related articles

Fulvestrant, a pure antiestrogen, shows promise in treating advanced breast cancer by down-regulating estrogen receptors (ER). It offers an alternative to tamoxifen, with potential for longer response durations in ER-positive breast cancer management.

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Endocrine therapy is crucial for all stages of breast cancer, targeting estrogen-sensitive tumors.
  • Tamoxifen, a selective estrogen receptor (ER) modulator, is a standard antiestrogen therapy but has limitations like partial agonist activity and resistance.
  • Tamoxifen resistance and side effects necessitate the development of novel endocrine agents.

Purpose of the Study:

  • To introduce fulvestrant, a novel pure antiestrogen and ER down-regulator, as a potential advancement in breast cancer endocrine therapy.
  • To compare the efficacy and safety of fulvestrant with existing therapies like tamoxifen and aromatase inhibitors.

Main Methods:

  • Fulvestrant was developed to eliminate tamoxifen's partial agonist activity and increase potency.

Related Experiment Videos

  • Clinical trials evaluated fulvestrant in advanced breast cancer, including settings after tamoxifen therapy.
  • Comparative studies assessed fulvestrant against anastrozole and ongoing trials compare it with tamoxifen in first-line therapy.

    • Main Results:

    • Fulvestrant exhibits high affinity for the ER without tamoxifen's agonist activities.
    • Promising clinical activity observed in advanced breast cancer post-tamoxifen treatment.
    • Fulvestrant demonstrated comparable efficacy to anastrozole in patients with relapsed or recurrent disease.

    Conclusions:

    • Fulvestrant represents a new class of pure antiestrogens (ER down-regulators) with a favorable profile for breast cancer endocrine therapy.
    • Its lack of ER agonist activity may lead to longer response durations compared to tamoxifen.
    • Fulvestrant is a promising therapeutic option for advanced breast cancer, particularly after tamoxifen failure, and warrants further investigation in various settings.